GB8531071D0 - Therapeutic compound - Google Patents

Therapeutic compound

Info

Publication number
GB8531071D0
GB8531071D0 GB858531071A GB8531071A GB8531071D0 GB 8531071 D0 GB8531071 D0 GB 8531071D0 GB 858531071 A GB858531071 A GB 858531071A GB 8531071 A GB8531071 A GB 8531071A GB 8531071 D0 GB8531071 D0 GB 8531071D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic compound
cyclobutyl
chlorophenyl
depression
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB858531071A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB8531071(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to GB858531071A priority Critical patent/GB8531071D0/en
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of GB8531071D0 publication Critical patent/GB8531071D0/en
Priority to IE310286A priority patent/IE59429B1/en
Priority to IN921/MAS/86A priority patent/IN163129B/en
Priority to ZA869078A priority patent/ZA869078B/xx
Priority to SI8612050A priority patent/SI8612050A8/sl
Priority to YU205086A priority patent/YU46033B/sh
Priority to PH34552A priority patent/PH22481A/en
Priority to DK585786A priority patent/DK170770B1/da
Priority to AT86309631T priority patent/ATE56942T1/de
Priority to IL80934A priority patent/IL80934A/xx
Priority to DE8686309631T priority patent/DE3674570D1/de
Priority to NZ218578A priority patent/NZ218578A/xx
Priority to GB8629568A priority patent/GB2184122B/en
Priority to EP86309631A priority patent/EP0230742B1/en
Priority to ES86309631T priority patent/ES2018163T4/es
Priority to FI865030A priority patent/FI90413C/fi
Priority to AU66442/86A priority patent/AU601167B2/en
Priority to CS869305A priority patent/CS259545B2/cs
Priority to DD86297631A priority patent/DD263050A5/de
Priority to UA4028642A priority patent/UA7206A1/uk
Priority to SU4028642A priority patent/SU1443796A3/ru
Priority to MX468486A priority patent/MX4684A/es
Priority to KR1019860010764A priority patent/KR940008913B1/ko
Priority to NO865093A priority patent/NO165540C/no
Priority to HU865232A priority patent/HU201901B/hu
Priority to PL1986263020A priority patent/PL149519B1/pl
Priority to JP61299806A priority patent/JPS62155240A/ja
Priority to PT83958A priority patent/PT83958B/pt
Priority to EG774/86A priority patent/EG17770A/xx
Priority to CN86108547A priority patent/CN1016245B/zh
Priority to CA000525648A priority patent/CA1266278A/en
Priority to US07/342,638 priority patent/US4929629A/en
Priority to US07/467,471 priority patent/US5068440A/en
Priority to GR90400895T priority patent/GR3001069T3/el
Priority to HRP-2050/86A priority patent/HRP930745B1/xx
Priority to LTRP1012A priority patent/LT2520B/xx
Priority to LV931268A priority patent/LV5455A3/xx
Priority to GEAP19941745A priority patent/GEP19970812B/en
Priority to NL300065C priority patent/NL300065I1/nl
Priority to LU90865C priority patent/LU90865I2/fr
Priority to NO2005022C priority patent/NO2005022I1/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB858531071A 1985-12-17 1985-12-17 Therapeutic compound Pending GB8531071D0 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound
IE310286A IE59429B1 (en) 1985-12-17 1986-11-25 N,N-dimethyl-1-(1-(4-chlorophenyl) cyclobutyl)-3-methyl butylamine hydrochloride monohydrate
IN921/MAS/86A IN163129B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-12-17 1986-11-28
ZA869078A ZA869078B (en) 1985-12-17 1986-12-02 Therapeutic compound
SI8612050A SI8612050A8 (sl) 1985-12-17 1986-12-02 Nova nehigroskopična oblika n,n-dimetil-1-1-(4-klorofenil) ciklobutil -3-metilbutilamin klorhidrata
YU205086A YU46033B (sh) 1985-12-17 1986-12-02 Novi henigroskopni oblikn,n-dimetil-1-/1-(4-hlorofenil) ciklobutil/-3-metilbuti lamin hlorhidrata
PH34552A PH22481A (en) 1985-12-17 1986-12-04 N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use
DK585786A DK170770B1 (da) 1985-12-17 1986-12-05 N,N-Dimetyl-1-[1-(4-(klorfenyl)-cyklobutyl]-3-metylbutylamin-hydroklorid, monohydrat, fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende forbindelsen samt anvendelse deraf.
FI865030A FI90413C (fi) 1985-12-17 1986-12-10 Menetelmä terapeuttisesti käyttökelpoisen N,N-dimetyyli-1-/1-(4-kloorifenyyli)-syklobutyyli/-3-metyylibutyyliamiinihydrokloridimonohydraatin valmistamiseksi
ES86309631T ES2018163T4 (es) 1985-12-17 1986-12-10 Un procedimiento para preparar hidrocloruro de N,N - dimetil - 1 - [(1 - (4 - clorofenil) ciclobutil ] - 3 - metilbutilamina monohidrato
IL80934A IL80934A (en) 1985-12-17 1986-12-10 N,n-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine hydrochloride monohydrate,process for its preparation and antidepressive compositions containing it
AT86309631T ATE56942T1 (de) 1985-12-17 1986-12-10 N,n-dimethyl-1-(1-(4-chlorophenyl)-cyclobutyl>- methylbutylamin-hydrochlorid, monohydrat und pharmazeutische zusammensetzungen, welche diese enthalten.
DE8686309631T DE3674570D1 (de) 1985-12-17 1986-12-10 N,n-dimethyl-1-(1-(4-chlorophenyl)-cyclobutyl)-3-methylbutylamin-hydrochlorid, monohydrat und pharmazeutische zusammensetzungen, welche diese enthalten.
NZ218578A NZ218578A (en) 1985-12-17 1986-12-10 N,n-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methyl butylamine hydrochloride monohydrate and pharmaceutical compositions
GB8629568A GB2184122B (en) 1985-12-17 1986-12-10 N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
EP86309631A EP0230742B1 (en) 1985-12-17 1986-12-10 N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it
AU66442/86A AU601167B2 (en) 1985-12-17 1986-12-11 Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate
CS869305A CS259545B2 (en) 1985-12-17 1986-12-15 Method of n,n-dimethyl-1-(1-/chlorphenyl/ cyclobutyl)-3-methylbutyl-amin-hydrochloride's monohydrate production
DD86297631A DD263050A5 (de) 1985-12-17 1986-12-15 Verfahren zur herstellung von n,n-dimethyl-1-[1-(4-chlorphenyl)-cyclobutyl]-3-methylbutylamin-hydrochlorid-monohydrat
UA4028642A UA7206A1 (uk) 1985-12-17 1986-12-15 Спосіб одержання гідрохлориду n,n-діметіл-1-[1-(4-хлорфеніл)-циклобутіл]-3-метілбутіламіна у вигляді моногідрату
SU4028642A SU1443796A3 (ru) 1985-12-17 1986-12-15 Способ получени гидрохлорида N,N-диметил-1- @ 1-(4-хлорфенил)-циклобутил @ -3-метилбутиламина в виде моногидрата
MX468486A MX4684A (es) 1985-12-17 1986-12-16 Clorohidrato de n,n-dimetil-1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina y proceso para su preparacion.
JP61299806A JPS62155240A (ja) 1985-12-17 1986-12-16 治療用化合物
KR1019860010764A KR940008913B1 (ko) 1985-12-17 1986-12-16 N,n-디메틸-1-[1-(4-클로로페닐)-사이클로부틸]-3-메틸부틸아민 염산염 일수화물의 제조방법
PL1986263020A PL149519B1 (en) 1985-12-17 1986-12-16 Method for manufacturing n,n-dimethyl-1-/1-(4-chlorphenyl)cyclobutyl/-3-methylbutyl amine hydrochloride monohydrate
NO865093A NO165540C (no) 1985-12-17 1986-12-16 Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n,n-dimetyl-1-(1-(4-klorfenyl)cyklobutyl)-3-metylbutylamin-hydroklorid-monohydrat.
HU865232A HU201901B (en) 1985-12-17 1986-12-16 Process for producing n,n-dimethyl-1-(1-)4-chloro-phenyl(-cyclobutyl)-3-methyl-butyl-amine-hydrochloride-monohydrate
PT83958A PT83958B (pt) 1985-12-17 1986-12-17 Processo de preparacao de mono-hidrato do hidrocloreto de n,n-dimetil-1-{1-(4-clorofenil)ciclobutil}-3-metilbutilamina
EG774/86A EG17770A (en) 1985-12-17 1986-12-17 A process for the preparation of therapeutic compound which is useful in the treatment of depression
CN86108547A CN1016245B (zh) 1985-12-17 1986-12-17 N，n-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁胺盐酸盐-水合物的制备方法
CA000525648A CA1266278A (en) 1985-12-17 1986-12-17 Therapeutic compound
US07/342,638 US4929629A (en) 1985-12-17 1989-04-19 Therapeutic compound
US07/467,471 US5068440A (en) 1985-12-17 1990-01-19 Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate
GR90400895T GR3001069T3 (en) 1985-12-17 1990-11-08 N,n-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it
HRP-2050/86A HRP930745B1 (en) 1985-12-17 1993-04-02 New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride
LTRP1012A LT2520B (lt) 1985-12-17 1993-09-20 N,n-dimetil-1(1-(4-chlorfenil)-ciklobutil)-3-m etilbutilamino hidrochlorido monohidrato gavimo budas
LV931268A LV5455A3 (lv) 1985-12-17 1993-11-25 N,N-dimetil-1-Ú1-(4-hlorfenil)-ciklobutil¾-3-metilbutilamina hidrohlorida monohidrata iegusanas metode
GEAP19941745A GEP19970812B (en) 1985-12-17 1994-01-20 New non-hygroscopic form of n,n-dimethyl-1-/1-(4-chlorophenyl) cyclobuthyl)-3-methylbutylamine hydrochloride
NL300065C NL300065I1 (nl) 1985-12-17 2001-10-04 N,N-dimethyl-1Ä1-(4-chloorfenyl)cyclobutylÜ-3-methylbutylamine-hydrochloride, monohydraat en farmaceutische preparaten, die deze bevatten.
LU90865C LU90865I2 (fr) 1985-12-17 2001-12-18 Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine
NO2005022C NO2005022I1 (no) 1985-12-17 2005-09-14 N-Dimetyl-1-(1-(4-klorfenyl)cyklobutylÜ-3-metylbutylamin (sibutramin hydroklorid)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
GB8531071D0 true GB8531071D0 (en) 1986-01-29

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
GB858531071A Pending GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Country Status (34)

Country Link
US (2) US4929629A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0230742B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS62155240A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR940008913B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1016245B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE56942T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU601167B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1266278A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS259545B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD263050A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3674570D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK170770B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG17770A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2018163T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI90413C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8531071D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP19970812B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3001069T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU201901B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE59429B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL80934A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN163129B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU90865I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX4684A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300065I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO165540C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ218578A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH22481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL149519B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT83958B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1443796A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA7206A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU46033B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA869078B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JPH07508281A (ja) * 1992-06-23 1995-09-14 セプラコア　インコーポレーテッド 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JPH08500093A (ja) * 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
WO2000043002A1 (en) * 1999-01-20 2000-07-27 Knoll Pharmaceutical Company Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
AU3757200A (en) 1999-03-19 2000-10-09 Knoll Gmbh Treatment of pulmonary hypertension
WO2000056306A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of osteoarthritis
HUP0200497A2 (en) * 1999-03-19 2002-08-28 Knoll Gmbh Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain
US6365631B1 (en) * 1999-03-19 2002-04-02 Knoll Pharmaceutical Company Method of treating sleep apnoea
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
AU3896900A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000056311A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
AU2003264968B2 (en) * 2002-10-05 2006-03-16 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2099755A2 (en) * 2006-11-20 2009-09-16 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
EP2131835A1 (en) * 2007-04-09 2009-12-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
KR101280786B1 (ko) * 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2590969B1 (en) 2010-07-06 2014-10-15 AstraZeneca AB Therapeutic agents 976
RU2591188C2 (ru) 2010-11-04 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
PL263020A1 (en) 1988-05-12
FI865030L (fi) 1987-06-18
NO2005022I1 (no) 2005-10-03
KR870005961A (ko) 1987-07-08
YU205086A (en) 1987-12-31
NO165540B (no) 1990-11-19
PT83958B (pt) 1989-05-12
FI865030A0 (fi) 1986-12-10
CN86108547A (zh) 1987-08-19
FI90413C (fi) 1994-02-10
IE863102L (en) 1987-06-17
GR3001069T3 (en) 1992-03-20
IL80934A (en) 1990-07-26
FI90413B (fi) 1993-10-29
CA1266278A (en) 1990-02-27
DD263050A5 (de) 1988-12-21
YU46033B (sh) 1992-12-21
EP0230742A1 (en) 1987-08-05
CN1016245B (zh) 1992-04-15
NZ218578A (en) 1989-04-26
EG17770A (en) 1991-03-30
NO165540C (no) 1991-02-27
JPH0144176B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-26
PH22481A (en) 1988-09-12
ES2018163T4 (es) 2012-06-14
JPS62155240A (ja) 1987-07-10
CS259545B2 (en) 1988-10-14
PT83958A (en) 1987-01-01
SU1443796A3 (ru) 1988-12-07
US4929629A (en) 1990-05-29
GEP19970812B (en) 1997-02-10
DK585786A (da) 1987-06-18
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
CS930586A2 (en) 1988-02-15
HUT45964A (en) 1988-09-28
DK170770B1 (da) 1996-01-15
AU601167B2 (en) 1990-09-06
PL149519B1 (en) 1990-02-28
DE3674570D1 (de) 1990-10-31
MX4684A (es) 1993-12-01
UA7206A1 (uk) 1995-06-30
AU6644286A (en) 1987-06-18
IN163129B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-08-13
ES2018163B3 (es) 1991-04-01
ZA869078B (en) 1987-07-29
NO865093D0 (no) 1986-12-16
IE59429B1 (en) 1994-02-23
LU90865I2 (fr) 2002-02-18
NO865093L (no) 1987-06-18
NL300065I1 (nl) 2001-12-01
HU201901B (en) 1991-01-28
EP0230742B1 (en) 1990-09-26
ATE56942T1 (de) 1990-10-15
DK585786D0 (da) 1986-12-05

Similar Documents

Publication Publication Date Title
PT83958A (en) Therapeutic compound
CA2003524A1 (en) Treatment of obesity
GEP20063773B (en) Steroid Sulphatase Inhibitors
ATE46080T1 (de) Pharmazeutische komposition.
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
ITRM930752A0 (it) Cartuccia a perdere di orecchini per la foratura del lobo auricolare erelativi fermi integrata con morsetto di presa auricolare.
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
DE3063339D1 (en) Peptides with pharmacological activity and medicines containing them
GB2209281B (en) Pharmaceutical compositions comprising an alpha-2 adrenoceptor antagonist
GR3001862T3 (en) Pharmaceutical preparation for tinea pedis
ES8702142A1 (es) Procedimiento para preparar un medicamento a base de 2-amino-3-carboetoxiamino-6-(4-fluoro-bencilamino)-piridina y 4-acetamido-fenol
ES8506661A1 (es) Procedimiento para la preparacion de un nuevo derivado de 2-tolil-morfolina util en terapeutica
IT1173502B (it) Procedimento per la purificazione di soluzioni contenenti fruttosio 2-6 difosfato (f-2,6-p2) e utilizzazione del composto cosi' ottenuto in terapia
ES289004U (es) Almohada terapeutica perfeccionada
IT208662Z2 (it) Chiodo per legano perfezionato con gambo dotato di una pluralita' di intaglia, disposti con andamento elicoidale.